Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial

Blood. 2023 May 25;141(21):2657-2661. doi: 10.1182/blood.2022019160.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1
  • Antigens, CD34
  • Flow Cytometry
  • Humans
  • Leukemia, Myeloid, Acute*
  • Neoplastic Stem Cells
  • Prognosis
  • Stem Cells

Substances

  • Antigens, CD34
  • ADP-ribosyl Cyclase 1